Literature DB >> 21185730

Synthesis and in vivo evaluation of ¹⁸F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters.

Kazunori Kawamura1, Tomoteru Yamasaki, Fujiko Konno, Joji Yui, Akiko Hatori, Kazuhiko Yanamoto, Hidekatsu Wakizaka, Masanao Ogawa, Yuichiro Yoshida, Nobuki Nengaki, Toshimitsu Fukumura, Ming-Rong Zhang.   

Abstract

The purpose of this study was to synthesize two new positron emission tomography (PET) probes, N-(4-(2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl)phenyl)-9,10-dihydro-5-[¹⁸F]fluoroethoxy-9-oxo-4-acridine carboxamide ([¹⁸F]3) and quinoline-3-carboxylic acid [2-(4-{2-[7-(2-[¹⁸F]fluoroethoxy)-6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]ethyl}phenylcarbamoyl)-4,5-dimethoxyphenyl]amide ([¹⁸F]4), and to evaluate the potential of these PET probes for assessing the function of two major drug efflux transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). [¹⁸F]3 and [¹⁸F]4 were synthesized by ¹⁸F-alkylation of each O-desmethyl precursor with [¹⁸F]2-fluoroethyl bromide for injection as PET probes. In vitro accumulation assay showed that treatment with P-gp/BCRP inhibitors (1 and 2) enhanced the intracellular accumulation capacity of P-gp- and BCRP-overexpressing MES-SA/Dx5 cells. In PET studies, the uptake (AUC(brain[0-)₆₀ (min])) of [¹⁸F]3 and [¹⁸F]4 in wild-type mice co-injected with 1 were approximately sevenfold higher than that in wild-type mice, and the uptake of [¹⁸F]3 and [¹⁸F]4 in P-gp/Bcrp knockout mice were eight- to ninefold higher than that in wild-type mice. The increased uptake of [¹⁸F]3 and [¹⁸F]4 was similar to that of parent compounds ([¹¹C]1 and [¹¹C]2) previously described, indicating that radioactivity levels in the brain after injection of [¹⁸F]3 and [¹⁸F]4 are related to the function of drug efflux transporters. Also, these results suggest that the structural difference between parent compounds ([¹¹C]1 and [¹¹C]2) and fluoroethyl analogs ([¹⁸F]3 and [¹⁸F]4) do not obviously affect the potency against drug efflux transporters. In metabolite analysis of mice, the unchanged form in the brain and plasma at 60 min after co-injection of [¹⁸F]4 plus 1 were higher (95% for brain; 81% for plasma) than that after co-injection of [¹⁸F]3 plus 1. [¹⁸F]4 is a promising PET probe to assess the function of drug efflux transporters. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21185730     DOI: 10.1016/j.bmc.2010.12.004

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  9 in total

1.  Brain distribution and bioavailability of elacridar after different routes of administration in the mouse.

Authors:  Ramola Sane; Sagar Agarwal; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2012-05-18       Impact factor: 3.922

Review 2.  PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Authors:  Severin Mairinger; Thomas Erker; Markus Muller; Oliver Langer
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

3.  Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein.

Authors:  Bernd Dörner; Claudia Kuntner; Jens P Bankstahl; Thomas Wanek; Marion Bankstahl; Johann Stanek; Julia Müllauer; Florian Bauer; Severin Mairinger; Wolfgang Löscher; Donald W Miller; Peter Chiba; Markus Müller; Thomas Erker; Oliver Langer
Journal:  Bioorg Med Chem       Date:  2011-02-26       Impact factor: 3.641

4.  Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113.

Authors:  Severin Mairinger; Thomas Wanek; Claudia Kuntner; Yaprak Doenmez; Sabine Strommer; Johann Stanek; Elena Capparelli; Peter Chiba; Markus Müller; Nicola A Colabufo; Oliver Langer
Journal:  Nucl Med Biol       Date:  2012-09-13       Impact factor: 2.408

5.  Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.

Authors:  Ramola Sane; Sagar Agarwal; Rajendar K Mittapalli; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2013-02-08       Impact factor: 4.030

6.  Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier.

Authors:  Pavitra Kannan; Victor W Pike; Christer Halldin; Oliver Langer; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  Mol Pharm       Date:  2013-05-02       Impact factor: 4.939

7.  PET Tracers for Clinical Imaging of Breast Cancer.

Authors:  Iván Peñuelas; Inés Domínguez-Prado; María J García-Velloso; Josep M Martí-Climent; Macarena Rodríguez-Fraile; Carlos Caicedo; María Sánchez-Martínez; José A Richter
Journal:  J Oncol       Date:  2012-08-29       Impact factor: 4.375

8.  Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier.

Authors:  Renske M Raaphorst; Gert Luurtsema; Robert C Schuit; Esther J M Kooijman; Philip H Elsinga; Adriaan A Lammertsma; Albert D Windhorst
Journal:  ACS Chem Neurosci       Date:  2017-07-10       Impact factor: 4.418

9.  In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance.

Authors:  Pavitra Kannan; András Füredi; Sabina Dizdarevic; Thomas Wanek; Severin Mairinger; Jeffrey Collins; Theresa Falls; R Michael van Dam; Divya Maheshwari; Jason T Lee; Gergely Szakács; Oliver Langer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-15       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.